PerkinElmer

August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]
March 17, 2016
Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for […]
October 18, 2013

PerkinElmer Announce Financial Results for the Second Quarter of 2013

Perkin Elmer, a global leader focused on improving the health and safety of people and the environment, today reported financial results for the second quarter ended […]
Contact Us